Experimental Hematology & Oncology is an open access journal that encompasses all aspects of hematology and oncology with an emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with 'negative' results and basic science studies with provocative findings.
As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
Aims and scope
Articles
-
-
The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China
-
SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients
-
Macrophage, the potential key mediator in CAR-T related CRS
-
Leukemia incidence trends at the global, regional, and national level between 1990 and 2017
-
Breast cancer brain metastases: the last frontier
-
CD19: a biomarker for B cell development, lymphoma diagnosis and therapy
-
Metaplastic breast cancer: histologic characteristics, prognostic factors and systemic treatment strategies
-
Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis
-
The development of bispecific antibodies and their applications in tumor immune escape
Editors-in-Chief
Zihai Li, The Ohio State University
Delong Liu, New York Medical College
Kongming Wu, Tongji Medical Colleg
Editor's quote (Dr. Delong Liu)
"Like our companion journal, Journal of Hematology & Oncology, Experimental Hematology & Oncology publishes on all aspects of hematology and oncology, which are closely intertwined and rapidly evolving fields. It also emphasizes basic and translational research, as well as patient-oriented research and clinical trials with ‘negative’ or preliminary results. The journal is an international platform for sharing findings in these areas and adheres to fast turnaround times."
Follow
Annual Journal Metrics
-
Speed
34 days to first decision for reviewed manuscripts only
27 days to first decision for all manuscripts
56 days from submission to acceptance
12 days from acceptance to publicationCitation Impact
3.492 - 2-year Impact Factor
0.709 - Source Normalized Impact per Paper (SNIP)
0.941 - SCImago Journal Rank (SJR)
Usage
174,663 Downloads
48 Altmetric Mentions
On the blog
-
Looking beyond physical health for World Cancer Day 2020
24 January 2020
-
Breast Cancer Quiz 2019
30 September 2019
-
Sharing data for the benefit of children with cancer
09 September 2019
